Ï£Íû1£º£º
ÑõÆø¶Ô¶¯ÎïÉúÃüÖÁ¹ØÖ÷Òª£¬ÔõÑù¸ÐÊÜÑõÆøÒ»Ö±ÊÇ¿ÆÑ§½çÃÕÍÅÖ®Ò»¡£¡£¡£2019Äêŵ±´¶ûÐÄÀíѧ»òҽѧ½±ÊÚÓèÁËÃÀ¹ú°©Ö¢Ñ§¼ÒWilliam G. Kaelin Jr¡¢¡¢Ó¢¹úҽѧ¼ÒSir Peter J. RatcliffeºÍÃÀ¹úҽѧ¼ÒGregg L. Semenza,ÒÔ±íÑïËûÃÇÔÚ·¢Ã÷ϸ°ûÔõÑù¸ÐÖªºÍ˳ӦÑõÆø¹©Ó¦ÖÐËù×ö³öµÄÓÅÒìТ˳¡£¡£¡£È»¶ø£¬Ö×Áö΢ÇéÐÎÏÂHIF1¦Á½éµ¼µÄµÍÑõͨ·ÔõÑù±»Î¬³ÖÕâÒ»Ö÷ÒªÉúÎïѧÔÒòÉв»ÇåÎú¡£¡£¡£ÑõÆø¶Ô¶¯ÎïÉúÃüÖÁ¹ØÖ÷Òª£¬ÔõÑù¸ÐÊÜÑõÆøÒ»Ö±ÊÇ¿ÆÑ§½çÃÕÍÅÖ®Ò»¡£¡£¡£2019Äêŵ±´¶ûÐÄÀíѧ»òҽѧ½±ÊÚÓèÁËÃÀ¹ú°©Ö¢Ñ§¼ÒWilliam G. Kaelin Jr¡¢¡¢Ó¢¹úҽѧ¼ÒSir Peter J. RatcliffeºÍÃÀ¹úҽѧ¼ÒGregg L. Semenza,ÒÔ±íÑïËûÃÇÔÚ·¢Ã÷ϸ°ûÔõÑù¸ÐÖªºÍ˳ӦÑõÆø¹©Ó¦ÖÐËù×ö³öµÄÓÅÒìТ˳¡£¡£¡£È»¶ø£¬Ö×Áö΢ÇéÐÎÏÂHIF1¦Á½éµ¼µÄµÍÑõͨ·ÔõÑù±»Î¬³ÖÕâÒ»Ö÷ÒªÉúÎïѧÔÒòÉв»ÇåÎú¡£¡£¡£
¿ËÈÕ£¬ÄϹ¬NG28¼¯ÍÅ»ù´¡Ò½Ñ§ÔºÖܾüÖÇ¿ÎÌâ×éÓë²ÌÑÇ·Ç(ÄϾ©Å©Òµ´óѧ)¡¢¡¢×ÞÓÀ¿µ(ÉîÛÚÍåʵÑéÊÒ)ÏàÖúÔÚ¹ú¼ÊÖøÃûÔÓÖ¾Proceedings of the National Academy of Sciences of the United States of America£¨PNAS£©ÔÚÏß½ÒÏþÁËÖ×ÁöµÍÑõͨ·ÐÂÐ͵÷¿Ø»úÖÆ¼°ÐÂÐÍÃâÒßÁªºÏÖÎÁƵÄ×îÐÂÑо¿Ð§¹û¡°UFMylation, a supervisor of HIF1¦Á pathway and potential therapeutic target for anti-PD-1 combination therapy in hypoxic tumors¡±¡£¡£¡£
¸ÃÑо¿·¢Ã÷HIF1¦ÁµÄÓÌËØÐÞÊÎ (UFMylation)·´¿¹Æä·ºËØ»¯½µ½â¡¢¡¢Î¬³ÖÆäÂѰ×ÎȹÌÐÔ¡£¡£¡£»úÖÆÉÏ£¬ÓÌËØÐÞÊÎÒò×ÓE3£¨UFL1£©µÄȱʧ»ò HIF1¦Á UFMylationÐÞÊÎÍ»±äÌå¾ùÔöÌí HIF1¦Á Óë p53 µÄÁ¬Ïµ£¬´Ó¶øÔö½øÁËHIF1¦Á½µ½â¡£¡£¡£Ï¸°ûÄ£×ӺͶ¯ÎïÄ£×ÓÏÔʾ£º£ºÓÌËØÐÞÊÎÒò×ÓE1£¨UBA5£©µÄÇóý»ò HIF1¦Á UFMylationÐÞÊÎÍ»±äÌå¶¼»áϵ÷ HIF1¦Á ÎȹÌÐÔ£¬´Ó¶øÏÔÖøÒÖÖÆÖ×ÁöµÄÉú³¤ºÍ¿ªÕ¹¡£¡£¡£ÓÐÒâ˼µÄÊÇ£¬HIF1¦Á UFMylationÐÞÊÎÍ»±äµÄÖ×Áöϸ°ûÔ½·¢ÏìÓ¦anti-PD-1ÖÎÁÆ¡£¡£¡£UBA5 ÔÚÈéÏÙ°©ÁÙ´²×éÖ¯ÑùÆ·Öбí´ïÉϵ÷²¢ÓëHIF1¦Á±í´ïÕýÏà¹Ø£¬Í¬Ê±£¬UBA5Ñ¡ÔñÐÔÒÖÖÆ¼Á¿É½µµÍUFMylationÐÞÊλîÐÔºÍHIF1¦Á ÂѰף¬´Ó¶øÏÔÖøÔöǿСÊóÖ×ÁöÄ£×ÓÖеĿ¹ PD-1 ÁªºÏÖÎÁÆÐ§¹û£¬Í¹ÏÔÁÙ´²×ª»¯Ç±Á¦¡£¡£¡£Ñо¿Ð§¹ûÊ×´ÎÕ¹ÏÖÁËUFMylationÐÞÊÎÓëµÍÑõÐźÅͨ·µÄÆæÒìÁªÏµ£¬Õ¹ÏÖÁ˰ÐÏòHIF1¦Á UFMylationÐÞÊοÉÌá¸ßanti-PD-1¿¹ÌåÖÎÁÆÕâÒ»ÐÂÐÍÖ×ÁöÕ½ÂÔ¡£¡£¡£ÖµµÃÒ»ÌáµÄÊÇ£º£ºÃÀ¹ú¿ÆÑ§ÔºÔºÊ¿£¬Ö×ÁöµÍÑõͨ·ÁìÓò¹ú¼ÊÖøÃû¿ÆÑ§¼Ò£¬±öϦ·¨ÄáÑÇ´óѧ½ÌÊÚM. Celeste Simonµ£µ±¸Ã¸å¼þµÄѧÊõ±à¼¶Ô¸ÃÑо¿ÊÂÇéÓèÒԸ߶ÈÈϿɡ£¡£¡£
ÄϹ¬NG28¼¯ÍÅΪµÚһͨѶµ¥Î»£¬ÖܾüÖÇΪ×îºóͨѶ×÷Õß¡£¡£¡£¸ÃÑо¿ÊÂÇéÊܹú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîÄ¿¡¢¡¢ÄϹ¬NG28¼¯ÍŸßÌõÀíÈË²ÅÆô¶¯¾·ÑÖ§³Ö¡£¡£¡£
ÎÄÕÂÊÂÇéʾÒâͼ £¨PNAS 2025£©
Ï£Íû2£º£º
ÖܾüÖÇ¿ÎÌâ×éÔÚÂѰ×ÐÞÊÎÓëÐàÂõ¼°ÃâÒßµ÷¿ØÖÐҲȡµÃÆäËû³ÖÐøÐÔÏ£Íû
ÄÚÆ¤Ï¸°ûË¥×ÜÊÇѪ¹ÜÀÏ»¯µÄ½¹µãÍÆÊÖ£¬¸üÊǶàÖÖÐÄѪ¹Ü¼²²¡µÄÈ綯ÂöÖàÑùÓ²»¯¡¢¡¢¸ßѪѹ¡¢¡¢ÐÄË¥µÈÐÄѪ¹Ü¼²²¡µÄ¡°µ¼»ðË÷¡±¡£¡£¡£ÒÑÓÐÑо¿Åú×¢£¬Hippo-YAPÐźÅͨ·ÔÚÄÚÆ¤Ï¸°û¹¦Ð§µÄά³ÖÒÔ¼°¶àÖÖÐÄѪ¹Ü¼²²¡µÄ±¬·¢¿ªÕ¹ÖоßÓÐÖ÷Òª×÷Ó㬿ÉÊÇYAPÂѰ×ÊÇ·ñÄܹ»±¬·¢ÓÌËØ»¯ÐÞÊΣ¬ÒÔ¼°YAPµÄÓÌËØ»¯ÔÚѪ¹ÜÄÚÆ¤Ï¸°ûÐàÂõÖеÄ×÷Óû¹Éв»Ã÷È·¡£¡£¡£
2025Äê2ÔÂ21ÈÕ£¬ÄϹ¬NG28¼¯ÍÅÖܾüÖÇÍŶÓÓ뺼ÖÝʦ·¶´óѧÍô»¢ÍŶӡ¢¡¢ÖÐÄÏ´óÑ§ÏæÑÅÒ½Ôº°ØÓÂÆ½ÍŶӹ²Í¨Ñ¶ÔÚ¹ú¼Ê×ÅÃûÆÚ¿¯iScience (CellÐÂ×Ó¿¯JCR Q1)ÉϽÒÏþÌâΪ¡°UFMylation maintains YAP stability to promote vascular endothelial cell senescence¡±µÄÑо¿ÂÛÎÄ£¬·¢Ã÷ÄÚÆ¤Ï¸°ûYAPÊÇÐÂÐÍUFMylationÐÞÊε×Î¸ÃÐÞÊÎÔöÌíÁËÆäÂѰ×ÎȹÌÐÔ¡£¡£¡£ÓÐȤµÄÊÇ£¬ÐàÂõµÄÄÚÆ¤Ï¸°ûÖÐUFMylationÐÞÊλîÐÔÔöÌí½øÒ»²½Ôö½øÁ˵ÄYAPÎȹÌÐÔ£¬½øÒ»²½µ¼ÖÂÐàÂõÄÚÆ¤Ï¸°ûÖÐYAPµÄ»ýÀÛ£¬¼Ó¾çÄÚÆ¤Ï¸°ûÐàÂõ±íÐÍ¡£¡£¡£°ÐÏòYAP-UFMylationÐÞÊΣ¬¿ÉÒÔ¸ÄÉÆÄÚÆ¤Ï¸°ûÐàÂõ£¬Í¬Ê±¼õÇáÍíÄêСÊóµÄÐÄѪ¹ÜÐàÂõ±íÐÍ¡£¡£¡£¸ÃÑо¿Ê״η¢Ã÷ÁËUFMylationÐÞÊÎÓëÐàÂõÉúÎïѧµÄÁªÏµ£¬Ò²ÎªÐÄѪ¹ÜÐàÂõÌṩDZÔڰе㡣¡£¡£